Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
12
TIL Quote, Financials, Valuation and Earnings
Last price:
$8.00
Seasonality move
:
-29.14%
Day range:
$7.63 - $8.10
52-week range:
$5.67 - $42.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.44x
Volume:
18.9K
Avg. volume:
201.7K
1-year change:
-59.42%
Market cap:
$52.8M
Revenue:
--
EPS (TTM):
-$11.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TIL
Instil Bio, Inc.
|
-- | -$3.78 | -- | -107.39% | $29.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.62% | -58.59% | $467.62 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.5M | $0.67 | 11.91% | 37.43% | $88.65 |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-- | -$0.07 | -- | -75% | $3.25 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TIL
Instil Bio, Inc.
|
$7.78 | $29.00 | $52.8M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.03 | $31.21 | $3.7B | 14.17x | $0.00 | 0% | 3.54x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$314.40 | $467.62 | $41.7B | 139.29x | $0.00 | 0% | 11.30x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$59.87 | $88.65 | $11.5B | 22.43x | $0.00 | 0% | 3.79x |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
$3.17 | $3.25 | $126.2M | 3.16x | $0.25 | 7.89% | 65.99x |
|
SVRA
Savara, Inc.
|
$5.83 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TIL
Instil Bio, Inc.
|
41.36% | 5.678 | 70.11% | 14.03x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
0.42% | -0.079 | 0.8% | 22.01x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TIL
Instil Bio, Inc.
|
-$12K | -$15M | -32.04% | -50.54% | -- | -$10.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-$31K | -$2.4M | 27.4% | 27.49% | -225% | -$2M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Instil Bio, Inc. vs. Competitors
-
Which has Higher Returns TIL or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Instil Bio, Inc.'s net margin of 25.76%. Instil Bio, Inc.'s return on equity of -50.54% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital TILInstil Bio, Inc.-- -$2.01 $205.3M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About TIL or ACAD?
Instil Bio, Inc. has a consensus price target of $29.00, signalling upside risk potential of 272.75%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 41.67%. Given that Instil Bio, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Instil Bio, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TILInstil Bio, Inc.1 3 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is TIL or ACAD More Risky?
Instil Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock TIL or ACAD?
Instil Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TIL or ACAD?
Instil Bio, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Instil Bio, Inc.'s net income of -$13.6M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Instil Bio, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio, Inc. is -- versus 3.54x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TILInstil Bio, Inc.-- -- -- -$13.6M ACADACADIA Pharmaceuticals, Inc.3.54x 14.17x $278.6M $71.8M
-
Which has Higher Returns TIL or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Instil Bio, Inc.'s net margin of 16.99%. Instil Bio, Inc.'s return on equity of -50.54% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital TILInstil Bio, Inc.-- -$2.01 $205.3M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About TIL or ALNY?
Instil Bio, Inc. has a consensus price target of $29.00, signalling upside risk potential of 272.75%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $467.62 which suggests that it could grow by 48.74%. Given that Instil Bio, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Instil Bio, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TILInstil Bio, Inc.1 3 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is TIL or ALNY More Risky?
Instil Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock TIL or ALNY?
Instil Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TIL or ALNY?
Instil Bio, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Instil Bio, Inc.'s net income of -$13.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Instil Bio, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 139.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio, Inc. is -- versus 11.30x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TILInstil Bio, Inc.-- -- -- -$13.6M ALNYAlnylam Pharmaceuticals, Inc.11.30x 139.29x $1.1B $186.4M
-
Which has Higher Returns TIL or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Instil Bio, Inc.'s net margin of -3.91%. Instil Bio, Inc.'s return on equity of -50.54% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital TILInstil Bio, Inc.-- -$2.01 $205.3M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About TIL or BMRN?
Instil Bio, Inc. has a consensus price target of $29.00, signalling upside risk potential of 272.75%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.65 which suggests that it could grow by 48.07%. Given that Instil Bio, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Instil Bio, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TILInstil Bio, Inc.1 3 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is TIL or BMRN More Risky?
Instil Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock TIL or BMRN?
Instil Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TIL or BMRN?
Instil Bio, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Instil Bio, Inc.'s net income of -$13.6M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Instil Bio, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio, Inc. is -- versus 3.79x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TILInstil Bio, Inc.-- -- -- -$13.6M BMRNBioMarin Pharmaceutical, Inc.3.79x 22.43x $786.8M -$30.7M
-
Which has Higher Returns TIL or ORMP?
Oramed Pharmaceuticals, Inc. has a net margin of -- compared to Instil Bio, Inc.'s net margin of -382.1%. Instil Bio, Inc.'s return on equity of -50.54% beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.
Company Gross Margin Earnings Per Share Invested Capital TILInstil Bio, Inc.-- -$2.01 $205.3M ORMPOramed Pharmaceuticals, Inc.0.65% $1.13 $203.2M -
What do Analysts Say About TIL or ORMP?
Instil Bio, Inc. has a consensus price target of $29.00, signalling upside risk potential of 272.75%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could grow by 2.52%. Given that Instil Bio, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Instil Bio, Inc. is more attractive than Oramed Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TILInstil Bio, Inc.1 3 0 ORMPOramed Pharmaceuticals, Inc.0 0 0 -
Is TIL or ORMP More Risky?
Instil Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.249%.
-
Which is a Better Dividend Stock TIL or ORMP?
Instil Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.89% to investors and pays a quarterly dividend of $0.25 per share. Instil Bio, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TIL or ORMP?
Instil Bio, Inc. quarterly revenues are --, which are smaller than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Instil Bio, Inc.'s net income of -$13.6M is lower than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, Instil Bio, Inc.'s price-to-earnings ratio is -- while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio, Inc. is -- versus 65.99x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TILInstil Bio, Inc.-- -- -- -$13.6M ORMPOramed Pharmaceuticals, Inc.65.99x 3.16x -- $48.4M
-
Which has Higher Returns TIL or SVRA?
Savara, Inc. has a net margin of -- compared to Instil Bio, Inc.'s net margin of --. Instil Bio, Inc.'s return on equity of -50.54% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital TILInstil Bio, Inc.-- -$2.01 $205.3M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About TIL or SVRA?
Instil Bio, Inc. has a consensus price target of $29.00, signalling upside risk potential of 272.75%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 85.46%. Given that Instil Bio, Inc. has higher upside potential than Savara, Inc., analysts believe Instil Bio, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TILInstil Bio, Inc.1 3 0 SVRASavara, Inc.6 0 0 -
Is TIL or SVRA More Risky?
Instil Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock TIL or SVRA?
Instil Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TIL or SVRA?
Instil Bio, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Instil Bio, Inc.'s net income of -$13.6M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Instil Bio, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TILInstil Bio, Inc.-- -- -- -$13.6M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is up 15.9% over the past day.
Buy
72
CGNX alert for Feb 14
Cognex Corp. [CGNX] is up 0.31% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 2.47% over the past day.
